Inhibrx Biosciences Inc. cash flow to debt ratio of -121.29% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Inhibrx Biosciences Inc.'s free cash flow has increased -34.10% from $-197.01M last year to $-129.82M, signaling increasing performance

Inhibrx Biosciences Inc.'s debt to equity ratio is -0.28, signaling that the company spent its equity and risk bankruptcy.

Inhibrx Biosciences Inc.'s debt to equity ratio is -0.28, signaling that the company spent its equity and risk bankruptcy.

Inhibrx Biosciences Inc. has a net cash position, so leverage is healthy.

Inhibrx Biosciences Inc.'s interest coverage ratio is -9.45, which means that the company struggles to meet interest obligations, signaling financial risk.

Inhibrx Biosciences Inc.'s profit margin has decreased (101.19%) in the last year from 843.79K% to -10.01K%, signaling decreasing performance

Inhibrx Biosciences Inc.'s short-term assets of $132.83M exceed its short-term liabilities of $33.80M

Inhibrx Biosciences Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Inhibrx Biosciences Inc.'s return on equity of -563.89%, is lower than 15.00%, indicating bad performance

Inhibrx Biosciences Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Inhibrx Biosciences Inc. has insufficient public price history to evaluate earnings stability.

Inhibrx Biosciences Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Inhibrx Biosciences Inc. has negative free cash flow, indicating cash burn

Inhibrx Biosciences Inc.'s yearly earnings has decreased 108.30% since last year from $1.69B to $-140.06M, signaling decreasing performance

Inhibrx Biosciences Inc.'s yearly revenue has increased 550.00% since last year from $200.00K to $1.30M, signaling increasing performance

ROIC -76.97% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Inhibrx Biosciences Inc.'s 3-year revenue CAGR of -15.98% is negative, indicating declining revenue over the past 3 years

Inhibrx Biosciences Inc. has insufficient public price history to evaluate revenue consistency.

Inhibrx Biosciences Inc. has insufficient public price history to evaluate ROE consistency.

Inhibrx Biosciences Inc. has insufficient data to evaluate this check.

Inhibrx Biosciences Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Inhibrx Biosciences Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Inhibrx Biosciences Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Inhibrx Biosciences Inc. has insufficient data to evaluate this check.

Inhibrx Biosciences Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Inhibrx Biosciences Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

Inhibrx Biosciences Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue